{"id":"NCT00110396","sponsor":"EMD Serono","briefTitle":"Rebif New Formulation (RNF) in Relapsing Forms of Multiple Sclerosis","officialTitle":"A Multicentre, Single Arm, Open-Label, Phase IIIB Study to Evaluate the Safety and Antigenicity of Rebif® (Interferon-beta-1a) in Subjects With Relapsing Forms of Multiple Sclerosis","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2005-01","primaryCompletion":"2007-04","completion":"2007-04","firstPosted":"2005-05-09","resultsPosted":"2010-07-09","lastUpdate":"2015-07-15"},"enrollment":260,"design":{"allocation":"NON_RANDOMIZED","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Multiple Sclerosis"],"interventions":[{"type":"BIOLOGICAL","name":"Interferon-beta-1a FBS-free/HSA-free","otherNames":[]}],"arms":[{"label":"Rebif New Formulation Cohort","type":"EXPERIMENTAL"}],"summary":"The primary objective of the study is to compare the immunogenicity of the new fetal bovine serum (FBS)-free/human serum albumin (HSA)-free Rebif® formulation (RNF) to historical data.","primaryOutcome":{"measure":"Number of Participants Who Were Neutralising Antibody (NAb) Positive at the Week 96 Visit.","timeFrame":"96 weeks","effectByArm":[{"arm":"Rebif New Formulation (RNF) Cohort","deltaMin":45,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":10,"exclusionCount":15},"locations":{"siteCount":1,"countries":["United States"]},"refs":{"pmids":["17692727","18755819"],"seeAlso":["http://www.mslifelines.com"]},"adverseEventsSummary":{"seriousAny":{"events":15,"n":260},"commonTop":["Influenza like illness","Headache","Injection site erythema","Nausea","Back pain"]}}